A Modular, Multipart, Multiarm, Open-label, Phase I/II Study to Evaluate the Safety and Tolerability of CT7001 Alone and in Combination With Anti-cancer Treatments in Patients With Advanced Malignancies
Phase of Trial: Phase I/II
Latest Information Update: 12 Jun 2019
Price : $35 *
At a glance
- Drugs CT-7001 (Primary)
- Indications Acute myeloid leukaemia; Breast cancer; Cancer; Small cell lung cancer
- Focus Adverse reactions
- Sponsors Carrick Therapeutics
- 06 Jun 2019 Planned number of patients changed from 36 to 200.
- 06 Jun 2019 Planned End Date changed from 1 Dec 2018 to 1 Dec 2021.
- 06 Jun 2019 Planned primary completion date changed from 1 Sep 2018 to 1 Mar 2021.